Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crizotinib study in advanced lobular breast cancer or diffuse gastric cancer
2017-001680-20Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib and fulvestrant in Invasive Lobular Carcinoma (ILC) and Gastric adenocarcinoma (diffuse type) (DGC) (2 cohorts), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Confirmed response rate. Status: unknown.
02
Drugs
crizotinibfulvestrant
03
Conditions
Invasive Lobular Carcinoma (ILC)Gastric adenocarcinoma (diffuse type) (DGC)
Beyond the preview
Go deeper on 2017-001680-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001680-20.